Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms

2.

Coiffier

B

,

Brousse

N

,

Peuchmaur

M

, et al.

Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives)

.

Ann Oncol

.

1990

;

1

(

1

):

45

-

50

.

3.

Vose

J

,

Armitage

J

,

Weisenburger

D

;

International T-Cell Lymphoma Project

.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

.

J Clin Oncol

.

2008

;

26

(

25

):

4124

-

4130

.

4.

Sibon

D

,

Fournier

M

,

Briere

J

, et al.

Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials

.

J Clin Oncol

.

2012

;

30

(

32

):

3939

-

3946

.

5.

Federico

M

,

Rudiger

T

,

Bellei

M

, et al.

Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project

.

J Clin Oncol

.

2013

;

31

(

2

):

240

-

246

.

6.

Beltran

BE

,

Castro

D

,

De La Cruz-Vargas

JA

, et al.

The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma

.

Br J Haematol

.

2019

;

184

(

4

):

650

-

653

.

7.

Engsig

FN

,

Moller

MB

,

Hasselbalch

HK

,

Mahdi

B

,

Obel

N

.

Extreme neutrophil granulocytosis in a patient with anaplastic large cell lymphoma of T-cell lineage

.

APMIS

.

2007

;

115

(

6

):

778

-

783

.

8.

Siegert

W

,

Nerl

C

,

Agthe

A

, et al.

Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group

.

Ann Oncol

.

1995

;

6

(

7

):

659

-

664

.

9.

Goddard

DS

,

Yamanaka

Ki

,

Kupper

TS

,

Jones

DA

.

Activation of neutrophils in cutaneous T-cell lymphoma

.

Clin Cancer Res

.

2005

;

11

(

23

):

8243

-

8249

.

10.

Drieux

F

,

Ruminy

P

,

Sater

V

, et al.

Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay

.

J Mol Diagn

.

2021

;

23

(

8

):

929

-

940

.

11.

Streubel

B

,

Vinatzer

U

,

Willheim

M

,

Raderer

M

,

Chott

A

.

Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

.

Leukemia

.

2006

;

20

(

2

):

313

-

318

.

12.

Pechloff

K

,

Holch

J

,

Ferch

U

, et al.

The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma

.

J Exp Med

.

2010

;

207

(

5

):

1031

-

1044

.

13.

Dierks

C

,

Adrian

F

,

Fisch

P

, et al.

The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease

.

Cancer Res

.

2010

;

70

(

15

):

6193

-

6204

.

14.

Sprissler

C

,

Belenki

D

,

Maurer

H

, et al.

Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice

.

Blood Cancer J

.

2014

;

4

(

8

):

e240

.

15.

Ross

JA

,

Nagy

ZS

,

Cheng

H

,

Stepkowski

SM

,

Kirken

RA

.

Regulation of T cell homeostasis by JAKs and STATs

.

Arch Immunol Ther Exp

.

2007

;

55

(

4

):

231

-

245

.

16.

Egwuagu

CE

.

STAT3 in CD4+ T helper cell differentiation and inflammatory diseases

.

Cytokine

.

2009

;

47

(

3

):

149

-

156

.

17.

Rochman

Y

,

Spolski

R

,

Leonard

WJ

.

New insights into the regulation of T cells by gamma(c) family cytokines

.

Nat Rev Immunol

.

2009

;

9

(

7

):

480

-

490

.

18.

Waickman

AT

,

Park

JY

,

Park

JH

.

The common gamma-chain cytokine receptor: tricks-and-treats for T cells

.

Cell Mol Life Sci

.

2016

;

73

(

2

):

253

-

269

.

19.

Takemoto

S

,

Mulloy

JC

,

Cereseto

A

, et al.

Proliferation of adult T cell leukemia/lymphoma cells is associated with the constitutive activation of JAK/STAT proteins

.

Proc Natl Acad Sci U S A

.

1997

;

94

(

25

):

13897

-

13902

.

20.

Khoury

JD

,

Medeiros

LJ

,

Rassidakis

GZ

, et al.

Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma

.

Clin Cancer Res

.

2003

;

9

(

10 Pt 1

):

3692

-

3699

.

21.

Chiarle

R

,

Simmons

WJ

,

Cai

H

, et al.

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

.

Nat Med

.

2005

;

11

(

6

):

623

-

629

.

22.

Crescenzo

R

,

Abate

F

,

Lasorsa

E

, et al;

European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”

.

Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma

.

Cancer Cell

.

2015

;

27

(

4

):

516

-

532

.

23.

Odejide

O

,

Weigert

O

,

Lane

AA

, et al.

A targeted mutational landscape of angioimmunoblastic T-cell lymphoma

.

Blood

.

2014

;

123

(

9

):

1293

-

1296

.

24.

Manso

R

,

Sanchez-Beato

M

,

Gonzalez-Rincon

J

, et al.

Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma

.

Br J Haematol

.

2018

;

183

(

3

):

497

-

501

.

25.

Zhang

Q

,

Raghunath

PN

,

Xue

L

, et al.

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

.

J Immunol

.

2002

;

168

(

1

):

466

-

474

.

26.

Zamo

A

,

Chiarle

R

,

Piva

R

, et al.

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

.

Oncogene

.

2002

;

21

(

7

):

1038

-

1047

.

27.

Zhang

L

,

Pan

J

,

Dong

Y

, et al.

Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass

.

Cell Metab

.

2013

;

18

(

3

):

368

-

379

.

28.

Fathi

NN

,

Mohammad

DK

,

Gorgens

A

, et al.

Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression

.

Biochem Biophys Res Commun

.

2018

;

504

(

4

):

749

-

752

.

29.

Baxter

EJ

,

Scott

LM

,

Campbell

PJ

, et al;

Cancer Genome Project

.

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

.

Lancet

.

2005

;

365

(

9464

):

1054

-

1061

.

30.

James

C

,

Ugo

V

,

Le Couedic

JP

, et al.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

.

Nature

.

2005

;

434

(

7037

):

1144

-

1148

.

31.

Kralovics

R

,

Passamonti

F

,

Buser

AS

, et al.

A gain-of-function mutation of JAK2 in myeloproliferative disorders

.

N Engl J Med

.

2005

;

352

(

17

):

1779

-

1790

.

32.

Levine

RL

,

Wadleigh

M

,

Cools

J

, et al.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

.

Cancer Cell

.

2005

;

7

(

4

):

387

-

397

.

33.

Zeiser

R

,

Burchert

A

,

Lengerke

C

, et al.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

.

Leukemia

.

2015

;

29

(

10

):

2062

-

2068

.

34.

von Bubnoff

N

,

Ihorst

G

,

Grishina

O

, et al.

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)

.

BMC Cancer

.

2018

;

18

(

1

):

1132

.

35.

Pear

WS

,

Miller

JP

,

Xu

L

, et al.

Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow

.

Blood

.

1998

;

92

(

10

):

3780

-

3792

.

36.

Csepregi

JZ

,

Orosz

A

,

Zajta

E

, et al.

Myeloid-specific deletion of Mcl-1 yields severely neutropenic mice that survive and breed in homozygous form

.

J Immunol

.

2018

;

201

(

12

):

3793

-

3803

.

37.

Kopf

M

,

Baumann

H

,

Freer

G

, et al.

Impaired immune and acute-phase responses in interleukin-6-deficient mice

.

Nature

.

1994

;

368

(

6469

):

339

-

342

.

38.

Dzhagalov

I

,

Dunkle

A

,

He

YW

.

The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages

.

J Immunol

.

2008

;

181

(

1

):

521

-

528

.

39.

Dzhagalov

I

,

St John

A

,

He

YW

.

The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages

.

Blood

.

2007

;

109

(

4

):

1620

-

1626

.

40.

Oldham

KA

,

Parsonage

G

,

Bhatt

RI

, et al.

T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6

.

Eur Urol

.

2012

;

61

(

2

):

385

-

394

.

41.

Gunther

C

,

Carballido-Perrig

N

,

Kaesler

S

,

Carballido

JM

,

Biedermann

T

.

CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells

.

J Invest Dermatol

.

2012

;

132

(

3 Pt 1

):

626

-

634

.

42.

Groom

JR

,

Luster

AD

.

CXCR3 in T cell function

.

Exp Cell Res

.

2011

;

317

(

5

):

620

-

631

.

43.

Kim

SV

,

Mehal

WZ

,

Dong

X

, et al.

Modulation of cell adhesion and motility in the immune system by Myo1f

.

Science

.

2006

;

314

(

5796

):

136

-

139

.

44.

Murphy

KM

.

Permission to proceed: Jak3 and STAT5 signaling molecules give the green light for T helper 1 cell differentiation

.

Immunity

.

2008

;

28

(

6

):

725

-

727

.

45.

Gupta

M

,

Stenson

M

,

O'Byrne

M

, et al.

Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Ralpha as predictors of event-free survival in T-cell lymphoma

.

Ann Oncol

.

2016

;

27

(

1

):

165

-

172

.

46.

Futosi

K

,

Fodor

S

,

Mocsai

A

.

Neutrophil cell surface receptors and their intracellular signal transduction pathways

.

Int Immunopharmacol

.

2013

;

17

(

3

):

638

-

650

.

47.

Ellis

TN

,

Beaman

BL

.

Interferon-gamma activation of polymorphonuclear neutrophil function

.

Immunology

.

2004

;

112

(

1

):

2

-

12

.

48.

Melani

C

,

Mattia

GF

,

Silvani

A

, et al.

Interleukin-6 expression in human neutrophil and eosinophil peripheral blood granulocytes

.

Blood

.

1993

;

81

(

10

):

2744

-

2749

.

49.

Tormo

AJ

,

Letellier

MC

,

Sharma

M

,

Elson

G

,

Crabe

S

,

Gauchat

JF

.

IL-6 activates STAT5 in T cells

.

Cytokine

.

2012

;

60

(

2

):

575

-

582

.

50.

Yang

Y

,

Ochando

J

,

Yopp

A

,

Bromberg

JS

,

Ding

Y

.

IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation

.

J Immunol

.

2005

;

174

(

5

):

2720

-

2729

.

51.

Fujisawa

M

,

Nguyen

TB

,

Abe

Y

, et al.

Clonal germinal center B cells function as a niche for T-cell lymphoma

.

Blood

.

2022

;

140

(

18

):

1937

-

1950

.

52.

Zhang

Q

,

Zhao

K

,

Shen

Q

, et al.

Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6

.

Nature

.

2015

;

525

(

7569

):

389

-

393

.

53.

Chang

YP

,

Chen

CL

,

Chen

SO

, et al.

Autophagy facilitates an IFN-gamma response and signal transduction

.

Microbes Infect

.

2011

;

13

(

11

):

888

-

894

.

54.

Rojas

M

,

Olivier

M

,

Garcia

LF

.

Activation of JAK2/STAT1-alpha-dependent signaling events during Mycobacterium tuberculosis-induced macrophage apoptosis

.

Cell Immunol

.

2002

;

217

(

1-2

):

58

-

66

.

55.

Sakatsume

M

,

Igarashi

K

,

Winestock

KD

,

Garotta

G

,

Larner

AC

,

Finbloom

DS

.

The Jak kinases differentially associate with the alpha and beta (accessory factor) chains of the interferon gamma receptor to form a functional receptor unit capable of activating STAT transcription factors

.

J Biol Chem

.

1995

;

270

(

29

):

17528

-

17534

.

56.

Cascio

G

,

Martin-Cofreces

NB

,

Rodriguez-Frade

JM

, et al.

CXCL12 regulates through JAK1 and JAK2 formation of productive immunological synapses

.

J Immunol

.

2015

;

194

(

11

):

5509

-

5519

.

57.

Soldevila

G

,

Licona

I

,

Salgado

A

,

Ramirez

M

,

Chavez

R

,

Garcia-Zepeda

E

.

Impaired chemokine-induced migration during T-cell development in the absence of Jak 3

.

Immunology

.

2004

;

112

(

2

):

191

-

200

.

58.

Murray

HW

,

Tsai

CW

,

Liu

J

,

Ma

X

.

Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18

.

Infect Immun

.

2006

;

74

(

7

):

4370

-

4374

.

59.

Kallam

A

,

Witzig

TE

,

Roschewski

MJ

, et al.

Phase II multi-center study of ruxolitinib phosphate for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL)

.

J Clin Oncol

.

2019

;

37

(

15_suppl

):

e19063

.

60.

Moskowitz

AJ

,

Ghione

P

,

Jacobsen

E

, et al.

A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

.

Blood

.

2021

;

138

(

26

):

2828

-

2837

.

61.

Kim

W-S

,

Yoon

D-H

,

Eom

H-S

, et al.

A phase I/II study (JACKPOT8) of DZD4205, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma

.

Blood

.

2020

;

136

(

Supplement 1

):

19

-

20

.